Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Manvir Bains"'
Autor:
Wazim Mohammed Ismail, Amelia Mazzone, Flavia G. Ghiraldini, Jagneet Kaur, Manvir Bains, Amik Munankarmy, Monique S. Bagwell, Stephanie L. Safgren, John Moore-Weiss, Marina Buciuc, Lynzie Shimp, Kelsey A. Leach, Luis F. Duarte, Chandandeep S. Nagi, Saul Carcamo, Chi-Yeh Chung, Dan Hasson, Neda Dadgar, Jian Zhong, Jeong-Heon Lee, Fergus J. Couch, Alexander Revzin, Tamas Ordog, Emily Bernstein, Alexandre Gaspar-Maia
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-19 (2023)
MacroH2A histone variants are shown to mark a subset of enhancers in both normal and cancer cells. In mice, macroH2A deficiency is shown to facilitate increased activity of transcription stem cell-associated transcription factors.
Externí odkaz:
https://doaj.org/article/687c1bfb1c8f4aa091d8d2f3ab0a9055
Autor:
Andrea L. Kasinski, Kayla Gates, Jenna Clingerman, Chennan Li, Manvir Bains, Ikjot Singh Sohal, Jihye Son, Nadia A. Lanman, Alejandra Agredo, Arpita S. Pal
Supplementary Data from Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9e9f80eb4de886d06698dd39359a55b
https://doi.org/10.1158/0008-5472.22429852
https://doi.org/10.1158/0008-5472.22429852
Autor:
Andrea L. Kasinski, Kayla Gates, Jenna Clingerman, Chennan Li, Manvir Bains, Ikjot Singh Sohal, Jihye Son, Nadia A. Lanman, Alejandra Agredo, Arpita S. Pal
EGFR inhibitors (EGFRi) are standard-of-care treatments administered to patients with non–small cell lung cancer (NSCLC) that harbor EGFR alterations. However, development of resistance posttreatment remains a major challenge. Multiple mechanisms c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12538522dd78c2343de44d0c9a2a2429
https://doi.org/10.1158/0008-5472.c.6513478.v1
https://doi.org/10.1158/0008-5472.c.6513478.v1
Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET
Autor:
Arpita S. Pal, Alejandra Agredo, Nadia A. Lanman, Jihye Son, Ikjot Singh Sohal, Manvir Bains, Chennan Li, Jenna Clingerman, Kayla Gates, Andrea L. Kasinski
Publikováno v:
Cancer Res
EGFR inhibitors (EGFRi) are standard-of-care treatments administered to patients with non–small cell lung cancer (NSCLC) that harbor EGFR alterations. However, development of resistance posttreatment remains a major challenge. Multiple mechanisms c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac077bdc683d5ccc1c3514d40cecd022
https://doi.org/10.1158/0008-5472.can-20-0821
https://doi.org/10.1158/0008-5472.can-20-0821